Results 81 to 90 of about 9,177 (206)

The Paediatric BCG Vaccine Century: From Historical Success to Future Innovations

Acta Paediatrica, EarlyView.
ABSTRACT Aim The tuberculosis (TB) vaccine, Bacille‐Calmette‐Guérin (BCG), protects infants against severe forms of primary TB. Yet, it does not protect against pulmonary reactivation TB in adults. Methods A literature review was conducted between 1st January and 28th February 2025 using PubMed, Google Scholar and reports of the World Health ...
Stefan H. E. Kaufmann
wiley   +1 more source

Production of prostaglandin E2 in response to infection with modified vaccinia Ankara virus

Virology, 2012
AbstractProstaglandin E2 (PGE2) is an arachidonic acid (AA)-derived signaling molecule that can influence host immune responses to infection or vaccination. In this study, we investigated PGE2 production in vitro by cells infected with the poxvirus vaccine strain, modified vaccinia Ankara virus (MVA).
Ian T.D. Petty, David J. Pickup, April H. Spesock, Scott M. Laster, Justin Pollara   +4 more
openaire   +2 more sources

Vaccination in dermatology 2025: Update considering current recommendations of the German Standing Committee on Vaccination

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The immunosuppressive and immunomodulatory treatment of dermatological patients necessitates the regular review and updating of standard vaccinations and vaccines indicated for specific conditions. The German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute regularly publishes evidence‐based vaccination recommendations ...
Johanna Stoevesandt, Marc Schmalzing, Sophia Mohme, Matthias Goebeler   +3 more
wiley   +1 more source

Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application

Journal of Medical Virology, Volume 97, Issue 6, June 2025.
ABSTRACT Adeno‐associated virus (AAV) is a non‐enveloped DNA virus infecting a wide variety of species, tissues, and cell types, which is recognized as a safe and effective method for delivering therapeutic transgenes. AAV vector is the most popular viral gene delivery system in clinical delivery systems with unique and multiple advantages, such as ...
Ling Yin, Hongliang He, Hongliang Zhang, Yuhua Shang, Chengbo Fu, Songquan Wu, Tengchuan Jin   +6 more
wiley   +1 more source

Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway

PLoS Pathogens, 2014
Modified vaccinia virus Ankara (MVA) is an attenuated poxvirus that has been engineered as a vaccine against infectious agents and cancers. Our goal is to understand how MVA modulates innate immunity in dendritic cells (DCs), which can provide insights ...
Peihong Dai, Weiyi Wang, Hua Cao, Francesca Avogadri, Lianpan Dai, Ingo Drexler, Johanna A. Joyce, Xiao-Dong Li, Zhijian J. Chen, Taha Merghoub, Stewart Shuman, Liang Deng   +11 more
openalex   +3 more sources

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein

Journal of Virology, 2015
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice ...
A. Volz, A. Kupke, Fei Song, S. Jany, R. Fux, H. Shams‐Eldin, Jörg Schmidt, Christin Becker, M. Eickmann, S. Becker, G. Sutter   +10 more
semanticscholar   +1 more source

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers [PDF]

Pathogens, 2019
Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has spread to more than 70 countries worldwide since 2015. Despite active research, there are currently no licensed vaccines or therapeutics. We have previously reported the development of various adenoviral vectored vaccine candidates (ChAdOx1 ZIKV) with the ability to stimulate effective
César López-Camacho, Young Kim, Peter Abbink, Rafael Larocca, Juha Huiskonen, Dan Barouch, Arturo Reyes-Sandoval   +6 more
openaire   +5 more sources

Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines. [PDF]

Sci Rep, 2018
The replication-deficient orthopoxvirus modified vaccinia virus Ankara (MVA) is a promising vaccine vector against various pathogens and has an excellent safety record.
Altenburg AF, van Trierum SE, de Bruin E, de Meulder D, van de Sandt CE, van der Klis FRM, Fouchier RAM, Koopmans MPG, Rimmelzwaan GF, de Vries RD.   +9 more
europepmc   +2 more sources

Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics

Advanced Healthcare Materials, Volume 14, Issue 14, May 28, 2025.
This study investigates the potential of nanohybridized niclosamide as a therapeutic agent for Mpox, focusing on enhanced bioavailability, improved antiviral efficacy, and controlled drug release achieved through nanoengineering. The research emphasizes significant advancements in formulation strategies, mechanistic insights, and therapeutic outcomes ...
N. Sanoj Rejinold, Geun‐woo Jin, Jin‐Ho Choy   +2 more
wiley   +1 more source

Short-Lived Neutralizing Antibody Responses to Monkeypox Virus in Smallpox Vaccine–Naive Persons after JYNNEOS Vaccination

Emerging Infectious Diseases
JYNNEOS, a third-generation smallpox vaccine, is integral to monkeypox virus (MPXV) control efforts, but the durability of this modified vaccinia Ankara–Bavarian Nordic (MVA-BN) vaccine’s effectiveness is undefined.
Kara Phipps, Jennifer Yates, Jessica Pettit, Sean Bialosuknia, Danielle Hunt, Alan P. DuPuis, Anne Payne, William Lee, Kathleen A. McDonough   +8 more
doaj   +1 more source